SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date, amended upper-limb data and recent commercial-launch job postings. Many expect approval and anticipate short covering, while others stress that hiring and FDA rare-disease messaging are not proof of a favorable decision and point to the prior setbacks and remaining efficacy questions.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios reported FDA approval of a competing RRP treatment has fueled debate over the threat to Precigens PAPZIMEOS and whether the selloff is an overreaction; traders disagree on the therapies relative advantages and Precigens commercial head start. Attention is also turning to upcoming PRGN-2009 clinical data and a Q3 business update.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Shares are climbing to a fresh 52-week high as traders position ahead of the expected Q3 report, with BRIUMVI sales growth supporting optimism. Some also speculate about a potential buyout or short squeeze, but the takeover chatter is unconfirmed, and others attribute the move to earnings expectations and momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is under pressure after a steep decline, with traders focused on analyst price-target cuts and uncertainty ahead of its earnings report, as well as concerns about digital-ad growth. Bulls argue the selloff is disconnected from the companys profitability and growth, while bears warn of more downside if results or guidance disappoint; some also point to broader tech-market weakness.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas announced addition to the S&P 500, replacing Kenvue, is drawing attention, with traders weighing index-related buying against a possible sell-the-news reaction. Some posts also raise unverified claims about a DHS-related breach, but they do not appear to be the main catalyst.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicares post-TDAPA reimbursement contribution for DefenCath could decline through 2027 is driving the sharp selloff and debate over future revenue. Some traders view the comments as a serious pricing risk, while others argue DaVitas estimates are preliminary and point to CMSs more favorable payment assumptions; several describe the decline as an overreaction.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers upcoming quarterly earnings report is the main focus, with traders watching whether results and guidance can support the recent rally. Sentiment is split between hopes for an earnings beat and renewed strength in big pharma, and concerns about the companys growth outlook and patent expirations.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Lines stronger-than-expected third-quarter results and raised full-year outlook sparked a sharp rally, with traders debating whether heavy short interest could amplify the move. The reaction is mixed: some see evidence of a turnaround, while others point to profit-taking, fuel-cost pressures and lingering concerns about bookings and yields.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs Phase 3 REGAL trial reaching its prespecified 80th death event triggered final analysis and heightened anticipation of topline results for its GPS treatment in AML. Traders are sharply divided: bulls see potential for strong survival data, while skeptics question the trials control-arm assumptions and point to the share-price weakness as a reason for caution.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A sharp Nasdaq selloff has put QQQ in correction territory, with traders linking the pressure to weakness across technology and AI-related stocks, worries about returns on heavy AI spending, and rising-rate concerns. The community is split between bears expecting further losses and dip-buyers anticipating a relief bounce or short squeeze.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BA Stock Heads For Weekly Loss: CEO Maps Path To $10B Cash Flow, 737 Stabilization Slips Into 2027  

Equity

Boeing expects to reach the 737 production target of 47 aircraft per month in 2027, later than planned. 


Should You Invest in the iShares U.S. Industrials ETF (IYJ)?

GE Stock Rises Premarket: GE Aerospace CEO Assures Demand Remains 'Solid,' Retail Agrees    

CEO Larry Culp cited solid demand as third-quarter revenue rose 18% and profit jumped 30%. 


GE Stock Inches Up Overnight On $2.8B Navy Contract As Hypersonic Program Advances 

GE Aerospace will maintain F414 engines through 2031 while developing a new HyCAT hypersonic test vehicle. 

CAT Stock Heads For Second Weekly Loss: Is Caterpillar's AI Rally Fading? 

Caterpillar is losing momentum as investors weigh rich valuations, tariffs and execution risks.

GE Stock Charts Golden Cross As Strong Aviation Demand, Defense Growth Fuel Momentum 

A major factor behind GE Aerospace’s growth has been the ongoing strain within the global aircraft production system and defense demand.


South Korea's $350B U.S. Investment Pledge: ETFs That Could Gain

South Korea's $350B U.S. investment pledge could lift the country's export momentum while boosting key U.S. sectors. Here are some ETFs that may benefit.

iShares Trust - iShares U.S. Industrials ETF

Bullish Sentiment

<ul class="summary-bullets"><li>Boeing CEO Robert Ortberg said the 737 production could need additional time to reach stabilization,&nbsp;</li><li>The FAA approved the delayed 737 Max 10 last week, which has over 1,550 orders.&nbsp;</li><li>Boeing expects free cash flow to increase from $2 billion in 2026 to $10 billion by 2029.</li></ul>Boeing Co. (BA) stock is heading for a weekly loss as CEO Robert Ortberg outlined a path to $10 billion in free cash flow by 2029, with the company’s 737 production stabilization taking longer than expected. Boeing expects to reach its target production rate of 47 jets monthly in 2027, with cash flow improving over the next three years.&nbsp;<a href="https://stocktwits.com/symbol/BA">Boeing stock</a> edged up 0.2% overnight Tuesday after a 10% drop in regular trading.&nbsp;<h2 class="st-heading-2">Boeing’s 737 Production Ramp Faces Delays</h2>During the third-quarter (Q3) earnings call, Ortberg said Boeing is working to establish a manufacturing pace of 47 737 aircraft per month and needs additional time to sustain its targeted production rate.“On 737, we continue to work towards stabilizing production at 47 airplanes per month. Our factory key performance indicators are performing well, particularly in the final assembly, where we've seen a 40% improvement in rework since the start of last year. However, as I mentioned at a conference last month, it is taking us longer than we had expected to demonstrate performance at rate 47. We're making progress, but we still have more work to do, and I'm expecting it will take us into next year to get fully stable at this rate.”&nbsp;Boeing received U.S. approval last week for the 737 Max 10, its largest model in the 737 Max family, after a six-year wait. The plane has over 1,550 orders, making up more than 30% of Boeing’s total 737 Max orders. The delay followed safety checks after two deadly 737 Max 8 crashes in 2018 and 2019.&nbsp;<h2 class="st-heading-2">Boeing Sets Out Cash Flow Road Map</h2>Ortberg acknowledged that shareholders have struggled to predict how Boeing’s operational improvements would translate into the balance sheet. The company expects to generate roughly $2 billion in free cash flow in 2026, followed by approximately $3 billion in 2027. That 2027 outlook includes additional capital spending to develop the F/A-XX program, the U.S. Navy’s sixth-generation fighter jet contract.Boeing expects free cash flow to rise to about $6 billion in 2028 before reaching its $10 billion goal in 2029. Ortberg expects the financial recovery to pick up as some existing pressures ease.The 777X program will remain a drag in the near term. “With respect to program cash flow, we continue to expect 2027 to be a significant use of cash with 2028 improving before turning positive in 2029,” said CFO Jesus Malave of the 777X.&nbsp;Jefferies&nbsp;called Boeing’s free cash flow targets “disappointing,” noting that each year’s goal had slipped by about a year. In Q3, Boeing&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/boeing-q3-loss-narrows-sharply-ceo-says-we-have-more-work-to-do/cZUeX0gRBCk">reported&nbsp;</a>a loss of $0.34 per share, an improvement from a loss of $7.47 per share a year earlier but worse than analysts’ estimate of a loss of $0.25 per share, according to Fiscal.ai.&nbsp;<h2 class="st-heading-2">BA Stock: Retail View&nbsp;</h2>However, on Stocktwits, retail sentiment for BA improved to ‘extremely bullish’ from ‘bullish’. The stock recorded a 900% surge in message volume over the past 24 hours.&nbsp;A user&nbsp;<a href="https://stocktwits.com/Guvnor/message/667496470">said</a>, “Just turbulence. We'll be back to smooth flying soon.”BA stock has cratered 22% year-to-date.&nbsp;Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/jblu-stock-soars-to-best-day-in-18-months-after-ceo-geraghty-calms-credit-concerns-highlights-business-progress/cZUems9RBCU">JBLU Stock Soars To Best Day In 18 Months After CEO Geraghty Calms Credit Concerns, Highlights Business Progress</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Boeing 737 MAX 10 prepares to take off for its first flight at Renton Municipal Airport.

Boeing Co. (BA) stock is heading for a weekly loss as CEO Robert Ortberg outlined a path to $10 billion in free cash flow by 2029, with the company’s 737 production stabilization taking longer than expected. Boeing expects to reach its target production r

BA Stock Heads For Weekly Loss: CEO Maps Path To $10B Cash Flow, 737 Stabilization Slips Into 2027

Boeing Co

iShares Dow Jones US Aerospace & Defense

iShares U.S. Industrials ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

IYJ iShares U.S. Industrials ETF

Fundamentals

Latest IYJ News